Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sugen LLC
Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.
There are promising early signals from the novel mechanism, but Arcus’ fortunes remain tied to results from the TIGIT field.
C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.
VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.